Uniqure NV (QURE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Uniqure NV stock (QURE) is currently trading at $16.36. Uniqure NV PS ratio (Price-to-Sales) is 58.96. Analyst consensus price target for QURE is $38.00. WallStSmart rates QURE as Sell.
- QURE PE ratio analysis and historical PE chart
- QURE PS ratio (Price-to-Sales) history and trend
- QURE intrinsic value — DCF, Graham Number, EPV models
- QURE stock price prediction 2025 2026 2027 2028 2029 2030
- QURE fair value vs current price
- QURE insider transactions and insider buying
- Is QURE undervalued or overvalued?
- Uniqure NV financial analysis — revenue, earnings, cash flow
- QURE Piotroski F-Score and Altman Z-Score
- QURE analyst price target and Smart Rating
Uniqure NV
📊 No data available
Try selecting a different time range
Smart Analysis
Uniqure NV (QURE) · 8 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
Uniqure NV (QURE) Key Strengths (1)
100.67% of shares held by major funds and institutions
Supporting Valuation Data
Uniqure NV (QURE) Areas to Watch (7)
Company is destroying shareholder value
Losing money on operations
Earnings declining -18.20%, profits shrinking
Very expensive at 59.0x annual revenue
Very expensive at 5.1x book value
Modest revenue growth at 6.60%
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Uniqure NV (QURE) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 8 metrics analyzed, 1 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, EPS Growth. Some valuation metrics including Price/Sales (58.96), Price/Book (5.06) suggest expensive pricing. Growth concerns include Revenue Growth at 6.60%, EPS Growth at -18.20%, which may limit upside. Profitability pressure is visible in Return on Equity at -207.10%, Operating Margin at -901.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -207.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 6.60% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
QURE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
QURE's Price-to-Sales ratio of 58.96x sits near its historical average of 59.48x (14th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 15% below its historical high of 69.61x set in Mar 2026, and 43% above its historical low of 41.21x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for Uniqure NV (QURE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Uniqure NV operates as a stable business with moderate growth and solid fundamentals. Revenue reached 16M with 7% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 210% of revenue (34M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -78M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Uniqure NV.
Bottom Line
Uniqure NV offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Uniqure NV(QURE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.